TY - JOUR
T1 - Barriers to accessing methamphetamine treatment
T2 - A systematic review and meta-analysis
AU - Cumming, Craig
AU - Troeung, Lakkhina
AU - Young, Jesse T.
AU - Kelty, Erin
AU - Preen, David B.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background Methamphetamine use is associated with a range of poor health, social and justice outcomes. In many parts of the world increased methamphetamine use has been identified as a major public health concern. Methamphetamine treatment programmes have been effective in reducing and ceasing use, however a range of barriers have prevented these programmes being widely adopted by methamphetamine users. This review examines the barriers to accessing meth/amphetamine treatment identified in the literature. Methods Databases were systematically searched using relevant terms for peer-reviewed articles describing original research exploring the barriers to accessing treatment for meth/amphetamine use. Reviews and grey literature were excluded. Eleven studies conducted in 5 countries were included in data synthesis; this involved a systematic review of all 11 studies, and meta-analysis of the prevalence of barriers reported in 6 studies that published sufficient quantitative data. Results Psychosocial/internal barriers to accessing methamphetamine treatment were most prevalent across studies (10/11 studies). Meta-analysis confirmed the four most commonly endorsed barriers to treatment access across studies all psychosocial barriers were embarrassment or stigma (60%, 95% CI: 54–67%); belief that treatment was unnecessary (59%, 95% CI:54–65%); preferring to withdraw alone without assistance (55%, 95% CI:45–65); and privacy concerns (51%, 95% CI:44–59%). Conclusions The primary barriers to accessing methamphetamine treatment are psychosocial/internal. Services and treatment models that address these barriers are urgently required. There is a growing need for methamphetamine-appropriate treatment services. Further research evaluating treatment engagement and effectiveness for methamphetamine and polysubstance use, including the development of effective pharmacotherapies is warranted.
AB - Background Methamphetamine use is associated with a range of poor health, social and justice outcomes. In many parts of the world increased methamphetamine use has been identified as a major public health concern. Methamphetamine treatment programmes have been effective in reducing and ceasing use, however a range of barriers have prevented these programmes being widely adopted by methamphetamine users. This review examines the barriers to accessing meth/amphetamine treatment identified in the literature. Methods Databases were systematically searched using relevant terms for peer-reviewed articles describing original research exploring the barriers to accessing treatment for meth/amphetamine use. Reviews and grey literature were excluded. Eleven studies conducted in 5 countries were included in data synthesis; this involved a systematic review of all 11 studies, and meta-analysis of the prevalence of barriers reported in 6 studies that published sufficient quantitative data. Results Psychosocial/internal barriers to accessing methamphetamine treatment were most prevalent across studies (10/11 studies). Meta-analysis confirmed the four most commonly endorsed barriers to treatment access across studies all psychosocial barriers were embarrassment or stigma (60%, 95% CI: 54–67%); belief that treatment was unnecessary (59%, 95% CI:54–65%); preferring to withdraw alone without assistance (55%, 95% CI:45–65); and privacy concerns (51%, 95% CI:44–59%). Conclusions The primary barriers to accessing methamphetamine treatment are psychosocial/internal. Services and treatment models that address these barriers are urgently required. There is a growing need for methamphetamine-appropriate treatment services. Further research evaluating treatment engagement and effectiveness for methamphetamine and polysubstance use, including the development of effective pharmacotherapies is warranted.
KW - Barriers to treatment
KW - Methamphetamine
KW - Substance use disorder
KW - Systematic review
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84991206734&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2016.10.001
DO - 10.1016/j.drugalcdep.2016.10.001
M3 - Review article
C2 - 27736680
AN - SCOPUS:84991206734
SN - 0376-8716
VL - 168
SP - 263
EP - 273
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
ER -